Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

141.70
-7.0400-4.73%
Volume:1.76M
Turnover:252.09M
Market Cap:14.13B
PE:33.80
High:150.47
Open:150.47
Low:141.61
Close:148.74
52wk High:160.18
52wk Low:84.23
Shares:99.71M
Float Shares:98.00M
Volume Ratio:1.86
T/O Rate:1.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.19
EPS(LYR):3.40
ROE:14.96%
ROA:8.66%
PB:4.70
PE(LYR):41.68

Loading ...

Exploring Three High Growth Tech Stocks In The US Market

Simply Wall St.
·
16 hours ago

Neurocrine Biosciences Announces R&D Strategy Focused on Advancing Novel Therapies in Neuroscience and Endocrinology, Expanding CRF Platform for Metabolic Diseases, and Targeting Multiple New Medicine Approvals by Decade’s End

Reuters
·
Yesterday

Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns

Simply Wall St.
·
Dec 15

Chief Legal Officer Darin Lippoldt Reports Disposal of Neurocrine Biosciences Inc. Common Shares

Reuters
·
Dec 10

Neurocrine Biosciences Hosts 2025 R&D Day in San Diego

Reuters
·
Dec 10

RBC Raises Price Target on Neurocrine Biosciences to $180 From $160, Keeps Outperform Rating

MT Newswires Live
·
Dec 08

Neurocrine Biosciences (NBIX) valuation update after NBI-1070770 Phase 2 trial failure reshapes pipeline expectations

Simply Wall St.
·
Dec 07

Director Gary A. Lyons Reports Disposal of Neurocrine Biosciences Inc. Common Shares

Reuters
·
Dec 05

Eric Benevich, Chief Commercial Officer, reports disposal of Neurocrine Biosciences Inc. common shares

Reuters
·
Dec 03

Deutsche Bank Raises Price Target on Neurocrine Biosciences to $152 From $142, Keeps Hold Rating

MT Newswires Live
·
Dec 01

Neurocrine Biosciences, Inc. : Deutsche Bank Raises Target Price to $152 From $142

THOMSON REUTERS
·
Dec 01

Analysts Offer Insights on Healthcare Companies: Valneva (VALN) and Neurocrine (NBIX)

TIPRANKS
·
Nov 28

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Teva Pharmaceutical (TEVA)

TIPRANKS
·
Nov 27

Neurocrine Biosciences Director George J. Morrow Reports Disposal of Common Shares

Reuters
·
Nov 27

BRIEF-Neurocrine Biosciences Announces Publication Of Landmark Narrative Review On FDA-Approved Vmat2 Inhibitors Demonstrating Unique Profile Of Ingrezza® (Valbenazine) Capsules

Reuters
·
Nov 20

Neurocrine Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Nov 11

Morgan Stanley Trims Price Target on Neurocrine Biosciences to $173 From $178, Keeps Overweight Rating

MT Newswires Live
·
Nov 11

Neurocrine Biosciences Inc : Morgan Stanley Cuts Target Price to $173 From $178

THOMSON REUTERS
·
Nov 11

Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study

MT Newswires Live
·
Nov 11

Neurocrine says Phase 2 study of NBI-1070770 did not meet primary endpoint

TIPRANKS
·
Nov 11